Diplomat Pharmacy (DPLO) Receives Media Impact Rating of 0.13

Press coverage about Diplomat Pharmacy (NYSE:DPLO) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Diplomat Pharmacy earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.2094098121801 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Shares of NYSE:DPLO opened at $20.15 on Friday. The stock has a market capitalization of $1,492.49, a PE ratio of 23.99 and a beta of 1.32. Diplomat Pharmacy has a fifty-two week low of $14.00 and a fifty-two week high of $27.78. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.66 and a current ratio of 0.97.

How to Become a New Pot Stock Millionaire

Diplomat Pharmacy (NYSE:DPLO) last issued its earnings results on Monday, February 26th. The company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.02. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.17 billion. Diplomat Pharmacy had a return on equity of 8.89% and a net margin of 0.35%. The firm’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.08 EPS. sell-side analysts expect that Diplomat Pharmacy will post 0.94 EPS for the current fiscal year.

DPLO has been the topic of several recent analyst reports. Leerink Swann upgraded Diplomat Pharmacy from a “market perform” rating to an “outperform” rating and set a $23.00 price objective on the stock in a report on Monday, December 11th. Lake Street Capital initiated coverage on Diplomat Pharmacy in a report on Friday, February 9th. They set a “buy” rating and a $35.00 price objective on the stock. Credit Suisse Group upgraded Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and set a $28.00 price objective on the stock in a report on Thursday, January 25th. Barclays initiated coverage on Diplomat Pharmacy in a report on Thursday, March 8th. They set an “overweight” rating and a $27.00 price objective on the stock. Finally, Mizuho set a $25.00 price objective on Diplomat Pharmacy and gave the stock a “hold” rating in a report on Wednesday, January 24th. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $25.38.

In other news, Director Philip R. Hagerman sold 2,150,000 shares of the company’s stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $20.65, for a total value of $44,397,500.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. 30.20% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Diplomat Pharmacy (DPLO) Receives Media Impact Rating of 0.13” was originally reported by WKRB News and is the sole property of of WKRB News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.wkrb13.com/2018/03/31/diplomat-pharmacy-dplo-receives-media-impact-rating-of-0-13.html.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Insider Buying and Selling by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply